# Tuncay Göksel

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/tuncay-goksel/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,069 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 29 |
| i10-index | 49 |
| Last Known Institution | Ege University |
| OpenAlex ID | https://openalex.org/A5066553162 |
| ORCID iD | https://orcid.org/0000-0002-6089-1840 |
| Works | 187 |

## Researcher papers

- [Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-previously-untreated-pd-l1-expressing/)
- [Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-study-comparing-cisplatin-plus-gemcitabine-with-cisplatin-plus/)
- [Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-docetaxel-versus-placebo-plus-docetaxel-for-second-line/)
- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)
- [Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer](https://scholariq.org/papers/effect-of-first-line-serplulimab-vs-placebo-added-to-chemotherapy-on-survival-in/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Advanced Chemical Sensor Technologies](https://scholariq.org/topics/advanced-chemical-sensor-technologies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Ege University](https://scholariq.org/institutions/ege-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.